Patients who continued to receive pembrolizumab-based therapy after disease progression had longer overall survival than patients who stopped receiving pembrolizumab-based therapy.

Bicycle Therapeutics targets innovative cancer treatments with potential, like zelenectide pevedotin. Read here for an ...

During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment ...

US biotech major Gilead Sciences (Nasdaq: GILD) today announced positive top-line results from the Phase III ...

D modeling for robotic prostatectomyCost comparison of checkpoint inhibitors in high-risk bladder cancerAI-generated prostate ...

The data show that a regimen based on Trodelvy and PD-1 inhibitor Keytruda (pembrolizumab) was better than Keytruda plus ...

CytomX Therapeutics, Inc.’s CTMX share price has surged by 6.39%, which has investors questioning if this is right time to ...

In some patients with advanced triple-negative breast cancer, Trodelvy plus Keytruda was associated with an improvement in disease progression.

J.P. Morgan Asset Management today announced that Geng Ngarmboonanant will join the firm's Multi-Asset Solutions business as a managing director specializing in global business and investment strategy ...

Endocrine diseases pose significant health challenges, often contributing to premature morbidity and mortality. Traditional Randomized Controlled Trials ...

Shares of Iovance Biotherapeutics have plummeted post-Amtagvi approval. Read more to see a full investment analysis for IOVA ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...